000305044 001__ 305044
000305044 005__ 20251007112734.0
000305044 0247_ $$2doi$$a10.1038/s43856-025-01132-x
000305044 0247_ $$2pmid$$apmid:41034387
000305044 037__ $$aDKFZ-2025-02020
000305044 041__ $$aEnglish
000305044 1001_ $$0P:(DE-He78)79862c68074f8d78156f06f6e3c9801c$$aFan, Ziwen$$b0$$eFirst author
000305044 245__ $$aAssociation of leukocyte composition ratios from blood methylation with cancer mortality outcomes.
000305044 260__ $$a[London]$$bSpringer Nature$$c2025
000305044 3367_ $$2DRIVER$$aarticle
000305044 3367_ $$2DataCite$$aOutput Types/Journal article
000305044 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1759829229_6323
000305044 3367_ $$2BibTeX$$aARTICLE
000305044 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000305044 3367_ $$00$$2EndNote$$aJournal Article
000305044 500__ $$a#EA:C070#LA:C070#LA:C120#
000305044 520__ $$aLeukocyte composition ratios derived from blood genome-wide methylation (DNAm-derived LCRs), reflecting systemic inflammation, remain unclear in relation to various mortality outcomes.We performed an epigenome-wide analysis to identify the association of DNAm-derived LCRs with all-cause mortality, cancer-specific mortality, and lung-cancer-specific mortality in a large prospective cohort study with 17 years follow-up.Strong associations of multiple LCRs are seen for all mortality outcomes. The neutrophil-to-B-cell ratio was strongly associated with all-cause mortality (HR per SD increase, 1.20; 95% CI, 1.10-1.31), the neutrophil-to-lymphocyte ratio with cancer-specific mortality (HR, 1.28; 1.11-1.49), and the lymphocyte-to-monocyte ratio with lung-cancer-specific mortality (HR, 0.53; 0.38-0.75). The consistency of HR estimations across 11-year, 14-year, and 17-year follow-ups reinforces these findings. Several LCRs show stronger associations in females and younger participants.Our study identifies DNAm-derived LCRs as particularly useful measures for quantifying cancer mortality risk over long-term follow-ups exceeding a decade.
000305044 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000305044 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000305044 7001_ $$0P:(DE-He78)92820b4867c955a04f642707ecf35b40$$aEdelmann, Dominic$$b1$$udkfz
000305044 7001_ $$0P:(DE-He78)ad2dff19f16208697af82eaa31fa9d60$$aZhao, Zitong$$b2$$udkfz
000305044 7001_ $$aKöhler, Bruno Christian$$b3
000305044 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b4$$udkfz
000305044 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$eLast author$$udkfz
000305044 773__ $$0PERI:(DE-600)3096949-9$$a10.1038/s43856-025-01132-x$$gVol. 5, no. 1, p. 411$$n1$$p411$$tCommunications medicine$$v5$$x2730-664X$$y2025
000305044 909CO $$ooai:inrepo02.dkfz.de:305044$$pVDB
000305044 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79862c68074f8d78156f06f6e3c9801c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000305044 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92820b4867c955a04f642707ecf35b40$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000305044 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ad2dff19f16208697af82eaa31fa9d60$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000305044 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000305044 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000305044 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000305044 9141_ $$y2025
000305044 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000305044 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000305044 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:36:49Z
000305044 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:36:49Z
000305044 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review, Anonymous peer review, Double anonymous peer review$$d2024-04-10T15:36:49Z
000305044 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-04-10T15:36:49Z
000305044 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000305044 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-28
000305044 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000305044 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-28
000305044 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-28
000305044 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-28
000305044 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-28
000305044 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000305044 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPrimäre Krebsprävention$$x1
000305044 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000305044 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000305044 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000305044 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000305044 980__ $$ajournal
000305044 980__ $$aVDB
000305044 980__ $$aI:(DE-He78)C070-20160331
000305044 980__ $$aI:(DE-He78)C060-20160331
000305044 980__ $$aI:(DE-He78)HD01-20160331
000305044 980__ $$aUNRESTRICTED